Gloucester Reports Positive Results From Phase II Study of Lymphoma Drug

kavin submitted, created time 6 months 2 weeks (www.redorbit.com)

Gloucester Pharmaceuticals has reported positive data from a Phase II trial of romidepsin, a novel, cyclic peptide, pan-HDAC inhibitor under investigation for hematologic malignancies.

The study conducted by the US National Cancer Institute is a seven-arm, phase II, open-label trial of romidepsin in patients with cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL). The study enrolled 71 CTCL patients in three arms of the study that received romidepsin. Patients received 14mg/m2 of romidepsin infused on days one, eight and 15 every 28 days

1 comment | Blog It | Email It | Keywords: cancer lymphomas cancer drugs hematologic malignancies pan-HDAC nhibitor romidepsin